| 臺大學術典藏 |
2020-04-28T07:25:38Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Chih-Hung Hsu;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Yeh K.-H.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:38Z |
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection
|
Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; CHIH-HUNG HSU; Yeh K.-H.; Wang S.-M.; Tang C.; Chang K.-J.; Liang J.-T.;Huang K.-C.;Lai H.-S.;Lee P.-H.;Cheng Y.-M.;Hsu H.-C.;Cheng A.-L.;Chih-Hung Hsu;Yeh K.-H.;Wang S.-M.;Tang C.;Chang K.-J.; Liang J.-T.; Huang K.-C.; Lai H.-S.; Lee P.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
CHIH-HUNG HSU; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Chih-Hung Hsu;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:36Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang C.-H.; Chen M.-C.; Cheng A.-L.; CHIH-HUNG HSU; Yeh K.-H.; Yu Y.-C.; Whang-Peng J.; Yang P.-C.; Yang C.-H.;Chen M.-C.;Cheng A.-L.;Chih-Hung Hsu;Yeh K.-H.;Yu Y.-C.;Whang-Peng J.;Yang P.-C. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Chih-Hung Hsu;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; CHIH-HUNG HSU; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:34Z |
A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus
|
Pei Y.Y.;Kuo S.-H.;Yeh K.-H.;Chuang S.-E.;Chih-Hung Hsu;Wen C.C.;Lin H.-I.;Gao M.;Cheng A.-L.; Pei Y.Y.; Kuo S.-H.; Yeh K.-H.; Chuang S.-E.; CHIH-HUNG HSU; Wen C.C.; Lin H.-I.; Gao M.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:31Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
CHIH-HUNG HSU;Cheng A.-L.;Hsu W.-L.;Tsai Y.-C.;Hsu C.;Yang C.-H.;Yeh K.-H.;Lin C.-C.; Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2020-04-28T07:25:26Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.; CHIH-HUNG HSU; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. ;Chih-Hung Hsu ;Chen L.-T. ;Lu Y.-S. ;Lin C.-H. ;Yeh P.-Y. ;Jeng H.-J. ;Gao M. ;Yeh K.-H. ;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H. ;Cheng A.-L. ;Lin C.-W. ;Chih-Hung Hsu ;Wu M.-S. ;Yeh K.-H. ;Tzeng Y.-S. ;Chen L.-T.; Kuo S.-H.; Cheng A.-L.; Lin C.-W.; CHIH-HUNG HSU; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:17Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; Cheng A.-L.; CHIH-HUNG HSU; Lin C.-C.; Huang T.-C.; Guo J.-C.; Guo J.-C.;Huang T.-C.;Lin C.-C.;Hsieh M.-S.;Chang C.-H.;Huang P.-M.;Lee J.-M.;Hsu F.-M.;Cheng J.C.-H.;Wang H.-P.;Yeh K.-H.;Cheng A.-L.;Chih-Hung Hsu |
| 臺大學術典藏 |
2020-04-28T07:25:12Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
CHIH-HUNG HSU; Yeh K.-H.; Lin C.-C.; Huang T.-C.; Huang P.-M.; Kuo H.-Y.; Chang C.-H.; Wang C.-C.; Cheng J.C.-H.; Guo J.-C.; Guo J.-C.;Lin C.-C.;Huang T.-C.;Huang P.-M.;Kuo H.-Y.;Chang C.-H.;Wang C.-C.;Cheng J.C.-H.;Yeh K.-H.;Chih-Hung Hsu;Lee J.-M.; Lee J.-M. |
| 臺大學術典藏 |
2020-04-28T07:25:11Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Chia-Hsien Cheng J.; Lee J.-M.; Wang H.-P.; Huang P.-M.; Hsu F.-M.; Yeh K.-H.; Cheng A.-L.; Tzen K.-Y.; CHIH-HUNG HSU; Lin C.-C.; Wu Y.-C.; Huang T.-C.; Huang T.-C.;Lin C.-C.;Wu Y.-C.;Chia-Hsien Cheng J.;Lee J.-M.;Wang H.-P.;Huang P.-M.;Hsu F.-M.;Yeh K.-H.;Cheng A.-L.;Tzen K.-Y.;Chih-Hung Hsu |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
Guo J.-C.;Lin C.-C.;Huang T.-C.;Huang P.-M.;Kuo H.-Y.;Chang C.-H.;Wang C.-C.;Chia-Hsien Cheng;Yeh K.-H.;Hsu C.-H.;Lee J.-M.; Guo J.-C.; Lin C.-C.; Huang T.-C.; Huang P.-M.; Kuo H.-Y.; Chang C.-H.; Wang C.-C.; CHIA-HSIEN CHENG; Yeh K.-H.; Hsu C.-H.; Lee J.-M. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Liu M.-Y.;Chiun Hsu;Lin J.-T.;Yeh K.-H.;Cheng A.-L.; Cheng A.-L.; Yeh K.-H.; Lin J.-T.; Chiun Hsu; Liu M.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Chiun Hsu; Yeh K.-H.; Hong R.-L.; Yang C.-H.; Lin M.-T.; Chen Y.-C.; Cheng A.-L.; Chiun Hsu;Yeh K.-H.;Hong R.-L.;Yang C.-H.;Lin M.-T.;Chen Y.-C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:24Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Yang C.-H.; Chiun Hsu; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Lin C.-C.; Lin C.-C.;Yeh K.-H.;Yang C.-H.;Chiun Hsu;Tsai Y.-C.;Hsu W.-L.;Cheng A.-L.;Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:14Z |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression
|
Chiun Hsu; Shen Y.-C.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Cheng A.-L.; Yeh K.-H.; Chiun Hsu; Cheng W.-F.; Lin Y.-L.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:12Z |
Erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)
|
Chiun Hsu; Shen Y.-C.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:12Z |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
Chen I.C.; Chiun Hsu; Chen Y.C.; Chien S.F.; Kao H.F.; Chang S.Y.; Hu F.C.; Yeh K.H. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.; Chen L.-T.; Lin Z.-Z.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Chiun Hsu; Lin Y.-L.; Shen Y.-C.;Li C.-P.;Yen C.-J.;Chiun Hsu;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:09Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.;Chen I.-C.;Chiun Hsu;Chang S.-Y.;Chien S.-F.;Chen Y.-C.;Hu F.-C.;Yang J.C.-H.;Cheng A.-L.;Yeh K.-H.; Kao H.-F.; Chen I.-C.; Chiun Hsu; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:07Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Chiun Hsu; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
